Research summary ·
Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This study looked at women with antiphospholipid syndrome, or APS. These women had issues linked to the placenta in a past pregnancy. Examples are a baby that grew too slowly, preeclampsia, or late baby loss. They asked if LMWH, a type of heparin, stops these issues coming back. This was a review that searched for earlier trials. They only took trials where people were put in groups by chance.
What they found
The search found 4007 records, and 2 trials were kept. In the TIPPS trial, women got dalteparin or no dalteparin. Of these, 21 women with APS were used in the review. The FRUIT trial gave 32 women with APS dalteparin plus aspirin, or aspirin alone. In FRUIT, the issues came back in 4 of 16 women given dalteparin. In the aspirin-only group, this was 3 to 6 of 16 women. The range is wide because some joint issues were not reported. The results did not show a clear gap between the groups. The data from the 2 trials could not be joined into one result.
What it means for patients
The authors say there is no high-quality proof from trials that LMWH helps. This applies to women with APS and past placenta issues. It covers women who did not have repeated miscarriages before. So the benefit of this drug for these women is still not known.
Why it is not certain yet
Only 2 trials were found for this review. The FRUIT trial had just 32 women with APS. The trials did not report results in a way that could be pooled. Some joint issues were not reported, so the numbers are not firm. A review can only be as good as the studies in it.
Source
Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review.
PubMed · PMID 42339498We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Antiphospholipid syndrome publications